• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by InflaRx N.V.

    6/27/25 4:05:32 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IFRX alert in real time by email
    6-K 1 ef20051261_6k.htm 6-K
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 6-K

    Report of Foreign Private
    Issuer Pursuant to Rule
    13a-16 or 15d-16 under the
    Securities Exchange Act
    of 1934
    For the month of June 2025
    Commission File
    Number: 001-38283

    InflaRx N.V.

    Winzerlaer Str. 2
    07745 Jena,
    Germany
    (+49) 3641508180

    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒ Form 40-F  ☐



    OTHER INFORMATION
     
    Change in Certifying Accountant
     
    On June 26, 2025, InflaRx N.V. (the “Company”) executed an engagement letter with KPMG AG Wirtschaftsprüfungsgesellschaft (“KPMG”) to engage KPMG as its independent registered public accounting firm for the fiscal year ended December 31, 2025. In connection with this engagement, the Company ceased to engage EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft (“EY”) as its independent registered public accounting firm. EY had served as the Company’s independent registered public accounting firm since the fiscal year ended December 31, 2020. The change in independent registered public accounting firm follows the results of the Company’s Annual General Meeting of Shareholders held, in accordance with Dutch law, on April 24, 2025, where the Company’s shareholders voted to approve KPMG Accountants N.V. for the external audit of the Company’s statutory annual accounts for the fiscal year ended December 31, 2025. The Company’s decision to make the change in auditor was not due to any disagreement with EY. EY did not resign or decline to stand for re-election and EY’s reports on the Company’s financial statements as of and for the year ended December 31, 2024 and as of and for the year ended December 31, 2023 and on internal control over financial reporting as of December 31, 2024 and as of December 31, 2023 were not qualified and did not contain an adverse or disclaimer of opinion.
     
    The Company will provide the additional disclosures in accordance with Item 16F regarding the predecessor auditor in its Form 20-F for the fiscal year ending December 31, 2025.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    Date: June 27, 2025
     
     
    INFLARX N.V.
       
     
    By:
    /s/ Niels Riedemann
       
    Niels Riedemann
       
    Chief Executive Officer
     


    Get the next $IFRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IFRX

    DatePrice TargetRatingAnalyst
    5/29/2025$2.00Strong Buy → Outperform
    Raymond James
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/5/2023$8.00Neutral → Buy
    Guggenheim
    2/28/2022Buy → Neutral
    Guggenheim
    11/8/2021$14.00 → $15.00Strong Buy
    Raymond James
    10/28/2021$14.00Outperform → Strong Buy
    Raymond James
    8/6/2021$11.00 → $10.00Outperform
    Raymond James
    8/6/2021$2.80 → $2.50Underperform
    Credit Suisse
    More analyst ratings

    $IFRX
    SEC Filings

    View All

    SEC Form 6-K filed by InflaRx N.V.

    6-K - InflaRx N.V. (0001708688) (Filer)

    8/7/25 8:12:58 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by InflaRx N.V.

    6-K - InflaRx N.V. (0001708688) (Filer)

    7/14/25 4:15:19 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by InflaRx N.V.

    6-K - InflaRx N.V. (0001708688) (Filer)

    6/27/25 4:05:32 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InflaRx Announces Participation in September Investor Conferences

    JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2025. Details are as follows: Cantor Global Healthcare Conference 2025September 3 - 5, 2025 in New York, NYFireside chat on September 4th at 9:10 AM ET InflaRx will also conduct one-on-one investor meetings on September 4th. A link to view the fireside chat live stream and its replay is available here. H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 8 - 10, 2025 in New York, NYPresentation on September 9th at 3:30

    8/21/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

    INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals for InflaRx-partnered C5a antibody BDB-001 in ANCA-associated vasculitis (AAV) were favorable, with Staidson expecting Phase 3 study initiationInflaRx working diligently toward unblinding of stopped Phase 3 pyoderma gangrenosum (PG) trial so that all data can be analyzed later this yearEnrollment began in BARDA funded JUST BREATHE Phase 2 platform clinical trial investigating vilobelimab and additional novel therapeutic candidates for acute respiratory distress syndrome (ARDS)Cash, cash equ

    8/7/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx to Report Second Quarter 2025 Results on August 7, 2025

    JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powe

    7/31/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InflaRx downgraded by Raymond James with a new price target

    Raymond James downgraded InflaRx from Strong Buy to Outperform and set a new price target of $2.00

    5/29/25 8:15:13 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on InflaRx with a new price target

    Cantor Fitzgerald initiated coverage of InflaRx with a rating of Overweight and set a new price target of $10.00

    4/29/25 8:10:45 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx upgraded by Guggenheim with a new price target

    Guggenheim upgraded InflaRx from Neutral to Buy and set a new price target of $8.00

    4/5/23 11:33:25 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Leadership Updates

    Live Leadership Updates

    View All

    InflaRx Appoints Jan Medina as Head of Investor Relations

    JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: "We are delighted to welcome Jan to our team. His experience, proven track record and deep network with investors and capital mark

    2/22/24 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

    Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug developmentDr. Chong to lead clinical development of InflaRx's portfolio of C5a/C5aR inhibitors JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development, medical affai

    6/28/23 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InflaRx N.V.

    SC 13G - InflaRx N.V. (0001708688) (Subject)

    4/24/23 4:47:08 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by InflaRx N.V.

    SC 13G - InflaRx N.V. (0001708688) (Subject)

    4/17/23 4:00:10 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by InflaRx N.V. (Amendment)

    SC 13G/A - InflaRx N.V. (0001708688) (Subject)

    2/13/23 12:01:42 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IFRX
    Financials

    Live finance-specific insights

    View All

    InflaRx to Report Second Quarter 2025 Results on August 7, 2025

    JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powe

    7/31/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx to Report First Quarter 2025 Results on May 7, 2025

    JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory media

    4/30/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

    JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned. InflaRx also announced that it will participate in two investor conferences. Details are as follows: Leerink Global Healthcare ConferenceMarch 9 - 12, 2025 in Miami Beach, FL InflaRx will conduct a fireside chat at the conference on March 10 at 10:40 AM ET and will participate in one-on-one-investor meetings. A link to regis

    2/25/25 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care